Vivera Pharmaceuticals Licenses TABMELT®, a Sublingual Pharmaceutical Drug-Delivery System for Cannabidiol (CBD)

Share This Post

Company to focus on benefits of CBD for non-addictive pain management and opioid, alcohol addiction recovery

NEWPORT BEACH, Calif.–(BUSINESS WIRE)– Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces the debut of TABMELT®, a sublingual drug delivery system that Vivera has exclusively licensed for the specific use for pharmaceutical cannabinoids, including cannabidiol (CBD), a non-psychoactive compound derived from hemp, and other hemp-derived and biosynthetic cannabinoid compounds.

“According to the Centers for Disease Control and Prevention, on average, 130 Americans die every single day from an opioid overdose,” said Dr. Jon Norman, Chief Scientific Officer at Vivera. “We believe CBD has several important roles to play in this national crisis. It may offer a non-addictive way to manage pain and may create an alternative to starting patients on opioids in the first place. In addition, it may hold promise as a way to ease the detox process for patients in drug or alcohol recovery.”

Internationally patented and U.S. patent-pending TABMELT® may optimize the pharmaceutical delivery of CBD by offering a sublingual, set-dose system, which may enhance bioavailability by largely avoiding first-pass metabolism through the liver.

“Vivera’s commitment to innovative research, product development, and providing non-addictive therapies and treatments to patients is the foundation of our work,” said Olivia Karpinski, Co-founder and Executive Vice President of Vivera. “Our goal is to provide a non-addictive solution to patients nationwide who seek to manage pain and opioid cessation and deterrence in a safer way.”

Vivera is headquartered in Newport Beach, California.

For more information, visit

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT® drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

For more information, visit

Forward-looking and cautionary statements:

The securities described herein, if any, have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of Vivera Pharmaceuticals securities in the United States. This news release may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera Pharmaceuticals, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera Pharmaceuticals and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera Pharmaceuticals future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera Pharmaceuticals’ expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera Pharmaceuticals, reference should be made to Vivera Pharmaceuticals continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera Pharmaceuticals CSE Listing Statement. The forward-looking information contained in this release is made as of the date of this release. Vivera Pharmaceuticals does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents of this press release.

View source version on

Investor Relations and Canadian Media Enquiries:
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
[email protected]

U.S. Media Inquiries:
Brenda Patterson for Vivera Pharmaceuticals, Inc.
[email protected]

Source: Vivera Pharmaceuticals, Inc.

Released April 30, 2019

Subscribe To Our Newsletter

read more about us

Do You Want To Boost Your Business?

drop us a line and keep in touch